Pfizer Inc. (PFE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeeking Alpha • 06/08/26
U.S. FDA Approves Pfizer's HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical NeedBusiness Wire • 06/08/26
Can Pfizer's Dividend Survive the Patent Cliff? This $10.5 Billion Cancer Bet Could Hold the Answer.The Motley Fool • 06/06/26
Pfizer's 6.7% Yield Looks Scary -- but the Dividend Story Is Stronger Than It SeemsThe Motley Fool • 06/06/26
Pfizer's monthly obesity shot has side-effect profile similar to Wegovy in midstage trialReuters • 06/06/26
Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer's GLP-1 RA BerobenatideBusiness Wire • 06/06/26
Chai Discovery Announces License Agreement with Pfizer to Accelerate Drug Discovery with AIBusiness Wire • 06/04/26
Pfizer Inc. (PFE) Presents at Jefferies Global Healthcare Conference 2026 TranscriptSeeking Alpha • 06/03/26
Pfizer's Obesity and Oncology Pipeline Sets Up a Catalyst-Rich 2026Zacks Investment Research • 06/02/26
Pfizer's BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal CancerBusiness Wire • 05/31/26